# What People Actually Do After Stopping

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/what-people-actually-do-after-stopping

> Average weight change in the year after stopping was +0.5% for people treated for obesity, and −1.3% for those treated for diabetes. That does not contradict the withdrawal trials. It answers a different question.

## Key points

- Mean weight change one year after stopping: +0.5% (obesity), −1.3% (diabetes).
- 19.6% restarted the same drug; 35.2% received an alternative treatment.
- In a withdrawal trial the placebo arm gets nothing else, which is what makes it a clean test.
- The authors note 'considerable individual-level variability', so the mean describes a population, not you.

Everyone knows that stopping a GLP-1 means the weight comes back. A large study of what happened to people who stopped semaglutide or tirzepatide in ordinary care found the average weight change over the following year was **0.5%** in people treated for obesity.[1] That is half of one percent, not half of the weight lost. The explanation is not that the trials were wrong.

## What the study found

*Weight change in people who discontinued semaglutide or tirzepatide in clinical practice.*

| Group | Baseline to stopping | Stopping to one year later |
| --- | --- | --- |
| Treated for obesity | −8.4% (95% CI −8.7 to −8.1) | +0.5% (95% CI 0.0 to 1.0) |
| Treated for type 2 diabetes | −4.4% (95% CI −4.7 to −4.2) | −1.3% (95% CI −1.6 to −1.0) |

The diabetes group kept losing. The obesity group gained back a fraction of a percent. Neither looks anything like the rebound described in trials of stopping.

## Why this does not contradict the trials

In a withdrawal trial, people randomized to placebo receive *nothing else*. That is the design, and it is what makes it a clean test of the drug. In SURMOUNT-4, people switched to placebo regained about 14% within a year, which we covered in [the tirzepatide timeline](https://glpwatchdog.org/research/tirzepatide-results-timeline).

Real patients do not receive nothing. In this study, **19.6% restarted the same medication** and **35.2% received an alternative obesity treatment**: 27.4% another drug, 13.7% a lifestyle modification visit, and 0.6% metabolic or bariatric surgery.[1]

> In the year after stopping, 19.6% restarted the same drug and 35.2% received another obesity treatment. The trial arm that regains everything is the arm where nothing else happens.

So the two findings answer different questions. The trials tell you what the drug was doing. This study tells you what happens to people, in a system where stopping is often a transition rather than an ending.

## A second study, and the flaw it shares

An independent 2026 analysis followed 4,182 patients for six months after their last recorded semaglutide or tirzepatide prescription and found much the same thing: **roughly two-thirds had stable weight or were still losing**.[2] Two datasets reaching the same answer carry more weight than one.

> **Both studies share a problem, and the second one measured it.** A last *recorded prescription* is not the same event as stopping the drug. The researchers had a language model read the clinical notes for 300 of these patients, and found documented discontinuation for only **119 of them (40%)**.[2] The other 60% may have switched pharmacy, changed provider, moved to cash-pay or compounded supply, or simply had their next prescription written somewhere the network cannot see.

That matters because someone who quietly kept taking the drug will not regain weight, and will be counted as a success of stopping. It is the single largest reason to hold any “people do fine after stopping” finding loosely.

To the authors’ credit, the sub-analysis answers its own objection as far as it can. Among the 119 whose records confirm they stopped, the pattern held: **72% did not regain weight**.[2] That is a much smaller number of people, but it is the number that addresses the question.

The same work made one further observation. Exercise counseling appeared in the notes of 26.2% of those with durable weight loss against 14.7% of those who regained (P = .04).[2] That figure measures what a clinician wrote down, not what a patient did, and documented counseling is a marker of engaged care as much as of exercise. It is consistent with the theme that what happens after stopping matters more than the stopping.

## The sentence that limits all of it

The authors write that there was **considerable individual-level variability**, and that phrase carries more weight than the averages above.[1] A mean change of +0.5% is entirely compatible with a substantial number of people regaining a great deal while others continued to lose.

Averages of this kind describe a population, not a trajectory. If you are deciding whether you can afford to stop, the average is reassuring but tells you very little about your own case, and what you do next appears to matter more than the stopping itself.

> **Do not read this as permission to stop casually.** The authors suggest that restarting or moving to another treatment may be why the average change was so small. A plan for what comes next appears to be doing the work here, and the most common reason people stop, cost, is also the reason they often cannot restart. Our [maintenance article](https://glpwatchdog.org/research/tirzepatide-maintenance-dose-trial) covers the alternative of reducing rather than stopping.

## What to take from it

- **Stopping is not a cliff for most people**, at least not within a year, and the catastrophic framing is overstated. A separate argument holds, though, that the cardiovascular cost may not appear in a weight number at all (see [the cardiovascular cost of stopping](https://glpwatchdog.org/research/the-cardiovascular-cost-of-stopping)).
- **What you do next is the variable.** Restarting or switching was common and appears to be doing much of the work.
- **Diabetes and obesity are different situations.** Those treating diabetes kept losing on average, and the authors put that down to readier access to weight-reducing medication.
- **Your own result may be nothing like the mean.** The authors say so explicitly, and it is the most important sentence in the paper.

## Frequently asked questions

### Do you regain all the weight after stopping a GLP-1?

Not on average, in ordinary care. Among people who discontinued semaglutide or tirzepatide, mean weight change over the following year was +0.5% in those treated for obesity and −1.3% in those treated for diabetes, with considerable variation between individuals.

### Why do trials show large regain then?

Because in a withdrawal trial the placebo group receives nothing else, which is what makes it a clean test of the drug. In practice, 19.6% of people restarted the same medication and 35.2% received an alternative treatment. The trial arm that regains everything is the arm where nothing else happens.

### How much does individual variation matter here?

Enormously. The authors specifically note considerable individual-level variability, which means a mean of +0.5% is compatible with many people regaining substantially while others keep losing. It describes a population rather than predicting a person.

### What did people do after stopping?

About one in five restarted the same medication. Roughly a third received an alternative obesity treatment: another medication in 27.4% of cases, a lifestyle modification visit in 13.7%, and metabolic or bariatric surgery in 0.6%.

### Does this mean stopping is safe?

It means the weight consequences at one year are smaller than the popular account, for people who do something else afterward. Whether stopping is advisable is a clinical question, and reducing rather than stopping is a third option with randomized evidence behind it.

## References

1. Gasoyan H, Schulte R, Boyer CB, et al. Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide. Diabetes, Obesity and Metabolism. 2026. PMID: 41816857. https://pubmed.ncbi.nlm.nih.gov/41816857/
2. Murugadoss K, Varma G, Venkatakrishnan AJ, et al. Weight trajectories after last tirzepatide or semaglutide prescription across a federated health network. Biology Methods & Protocols. 2026. PMID: 42163990. https://pubmed.ncbi.nlm.nih.gov/42163990/

---

Cite as: GLP Watchdog, Nora Bissett, "What People Actually Do After Stopping", published 2026-08-19, updated 2026-10-27. https://glpwatchdog.org/research/what-people-actually-do-after-stopping

Canonical HTML page: https://glpwatchdog.org/research/what-people-actually-do-after-stopping

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
